/VVOS
VVOS Stock - Vivos Therapeutics, Inc.
Healthcare|Medical - DevicesNASDAQ
$2.04-1.69%
$0.04 (-1.69%) • Jan 13
35
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.2
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).71
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.6%upside
Target: $2.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VVOS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.01 – $2.06
TARGET (TP)$2.25
STOP LOSS$1.87
RISK/REWARD1:1.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta6.86
52W High$7.95
52W Low$1.93
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $15.03M | $13.80M | $16.02M | $16.89M | $13.07M |
| Gross Profit | $9.02M | $8.27M | $10.02M | $12.60M | $10.41M |
| Gross Margin | 60.0% | 59.9% | 62.5% | 74.6% | 79.7% |
| Operating Income | $-11,171,000 | $-17,296,000 | $-25,031,000 | $-19,471,000 | $-8,709,129 |
| Net Income | $-11,136,000 | $-13,583,000 | $-23,845,000 | $-20,293,000 | $-12,057,000 |
| Net Margin | -74.1% | -98.4% | -148.8% | -120.2% | -92.3% |
| EPS | $-2.22 | $-11.14 | $-25.90 | $-23.89 | $-24.70 |
Company Overview
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
VVOSBeat Rate
41%
Last 17 quarters
Avg Surprise
-174.8%
EPS vs Estimate
Beats / Misses
7/9
1 met exactly
Latest EPS
$-0.49
Q4 2025
EPS Surprise History
Q1 24
-60.5%
$-3.05vs$-1.90
Q2 24
-39.3%
$-1.63vs$-1.17
Q3 24
+42.9%
$-0.60vs$-1.05
Q4 24
+42.9%
$-0.40vs$-0.70
Q1 25
+34.9%
$-0.28vs$-0.43
Q2 25
-2.3%
$-0.45vs$-0.44
Q3 25
-103.7%
$-0.55vs$-0.27
Q4 25
+7.5%
$-0.49vs$-0.53
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.46 | — | — | — |
Q4 2025 | Nov 19, 2025 | $-0.53 | $-0.49 | +7.5% | ✓ BEAT |
Q3 2025 | Aug 19, 2025 | $-0.27 | $-0.55 | -103.7% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.44 | $-0.45 | -2.3% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-0.43 | $-0.28 | +34.9% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.70 | $-0.40 | +42.9% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-1.05 | $-0.60 | +42.9% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-1.17 | $-1.63 | -39.3% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-1.90 | $-3.05 | -60.5% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-3.12 | $-1.75 | +43.9% | ✓ BEAT |
Q3 2023 | Aug 16, 2023 | $-3.75 | $-3.75 | 0.0% | = MET |
Q2 2023 | Jun 8, 2023 | $-4.25 | $-5.00 | -17.6% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-5.50 | $-5.00 | +9.1% | ✓ BEAT |
Q4 2022 | Dec 20, 2022 | $-0.28 | $-8.25 | -2846.4% | ✗ MISS |
Q4 2022 | Nov 25, 2022 | — | $-4.95 | — | — |
Q3 2022 | Aug 23, 2022 | — | $-8.27 | — | — |
Q2 2022 | May 16, 2022 | $-7.25 | $-6.50 | +10.3% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-4.00 | $-6.50 | -62.5% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-4.00 | $-4.75 | -18.8% | ✗ MISS |
Q2 2021 | May 17, 2021 | $-4.25 | $-4.75 | -11.8% | ✗ MISS |
Latest News
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $5.5
➖ NeutralBenzinga•Dec 3, 2025, 11:47 AM
Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate
➖ NeutralBenzinga•Nov 19, 2025, 09:08 PM
HC Wainwright & Co. Initiates Coverage On Vivos Therapeutics with Buy Rating, Announces Price Target of $7
📈 PositiveBenzinga•Nov 17, 2025, 12:31 PM
Vivos' Study Demonstrates Its Daytime-Nighttime Appliance Provides Relief, Quality Of Life Improvement In Children With Attention-Deficit/Hyperactivity Disorder, Obstructive Sleep Apnea
📈 PositiveBenzinga•Sep 30, 2025, 12:41 PM
Vivos Therapeutics Announces Peer-Reviewed Published Data Confirming That Vivos DNA Is Both Safe And Efficacious In Treating Children Suffering From OSA
📈 PositiveBenzinga•Sep 17, 2025, 12:34 PM
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $6.5
📈 PositiveBenzinga•Sep 9, 2025, 11:18 AM
Vivos Therapeutics shares are trading lower after the company reported mixed Q2 financial results.
📉 NegativeBenzinga•Aug 20, 2025, 03:53 PM
Vivos Therapeutics Unveils New Model
📈 PositiveThe Motley Fool•Aug 19, 2025, 09:55 PM
Vivos Therapeutics Q2 EPS $(0.55) Misses $(0.35) Estimate, Sales $3.820M Beat $3.783M Estimate
📉 NegativeBenzinga•Aug 19, 2025, 08:23 PM
Frequently Asked Questions about VVOS
What is VVOS's current stock price?
Vivos Therapeutics, Inc. (VVOS) is currently trading at $2.04 per share. The stock has moved -1.69% today.
What is the analyst price target for VVOS?
The average analyst price target for VVOS is $2.25, based on 1 analyst.
What sector is Vivos Therapeutics, Inc. in?
Vivos Therapeutics, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is VVOS's market cap?
Vivos Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does VVOS pay dividends?
No, Vivos Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADGM
Adagio Medical Holdings, Inc.
$0.92
Mkt Cap: $0.0B
AEMD
Aethlon Medical, Inc.
$2.53
Mkt Cap: $0.0B
ALUR
Allurion Technologies Inc.
$1.75
Mkt Cap: $0.0B
AMS
American Shared Hospital Services
$2.16
Mkt Cap: $0.0B
ANL
Adlai Nortye Ltd.
$1.58
Mkt Cap: $0.0B
COCH
Envoy Medical, Inc.
$0.68
Mkt Cap: $0.0B
CODX
Co-Diagnostics, Inc.
$5.89
Mkt Cap: $0.0B
LPCN
Lipocine Inc.
$9.45
Mkt Cap: $0.1B
NVNO
enVVeno Medical Corporation
$0.34
Mkt Cap: $0.0B
OSRH
OSR Holdings, Inc.
$0.68
Mkt Cap: $0.0B
Explore stocks similar to VVOS for comparison